These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25692619)

  • 21. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement.
    Stahlschmidt J; Cullinane C; Roberts P; Picton SV
    Med Pediatr Oncol; 1999 Dec; 33(6):551-7. PubMed ID: 10573578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
    Liu H; Du L; Wang R; Wei C; Liu B; Zhu L; Liu P; Liu Q; Li J; Lu SL; Xiao J
    Oncotarget; 2015 May; 6(13):11477-91. PubMed ID: 25909167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
    Kim SJ; Shin DY; Kim JS; Yoon DH; Lee WS; Lee H; Do YR; Kang HJ; Eom HS; Ko YH; Lee SH; Yoo HY; Hong M; Suh C; Kim WS
    Ann Oncol; 2016 Apr; 27(4):712-8. PubMed ID: 26861608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
    Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
    Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
    Cetin B; Coskun U; Yildiz R; Buyukberber S; Baykara M; Benekli M
    J Oncol Pharm Pract; 2011 Sep; 17(3):274-8. PubMed ID: 20215482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.
    Ito K; Mikami S; Tatsugami K; Masumori N; Shinohara N; Kondo T; Nakanishi S; Nagashima Y; Eto M; Kamba T; Kuroda N; Tomita Y; Matsuyama H; Onishi T; Tsushima T; Nakazawa H; Oya M; Ozono S; Naito S; Asano T
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1201-e1214. PubMed ID: 30224330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.
    Goebell PJ; Doehn C; Grüllich C; Grünwald V; Steiner T; Ehneß R; Welslau M
    Future Oncol; 2017 Jul; 13(17):1463-1471. PubMed ID: 28523933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.
    Milella M; Falcone I; Conciatori F; Matteoni S; Sacconi A; De Luca T; Bazzichetto C; Corbo V; Simbolo M; Sperduti I; Benfante A; Del Curatolo A; Cesta Incani U; Malusa F; Eramo A; Sette G; Scarpa A; Konopleva M; Andreeff M; McCubrey JA; Blandino G; Todaro M; Stassi G; De Maria R; Cognetti F; Del Bufalo D; Ciuffreda L
    Sci Rep; 2017 Feb; 7():43013. PubMed ID: 28220839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal Medullary Carcinoma: a Report of the Current Literature.
    Blas L; Roberti J; Petroni J; Reniero L; Cicora F
    Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SMARCB1/INI1 inactivation in renal medullary carcinoma.
    Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
    Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
    Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
    Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.
    Sodji Q; Klein K; Sravan K; Parikh J
    J Immunother Cancer; 2017 Aug; 5(1):62. PubMed ID: 28807004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cystic presentation of a renal medullary carcinoma in a young woman.
    Levi Sandri GB; Spoletini G; Lai Q; Mennini G; Rossi M
    Urologia; 2015; 82(2):124-6. PubMed ID: 25451881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal Medullary Carcinoma with an Aggressive Clinical Course: A Case Report and Review of the Literature.
    Kalavar MR; Ali S; Safarpour D; Kunnakkat SD
    Case Rep Oncol; 2017; 10(1):1-7. PubMed ID: 28203160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
    Weigelt B; Warne PH; Downward J
    Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
    Shapiro DD; Zacharias NM; Tripathi DN; Karki M; Bertocchio JP; Soeung M; He R; Westerman ME; Gao J; Rao P; Lam TNA; Jonasch E; Perelli L; Cheng EH; Carugo A; Heffernan TP; Walker CL; Genovese G; Tannir NM; Karam JA; Msaouel P
    Clin Transl Med; 2023 May; 13(5):e1267. PubMed ID: 37226898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.